Binds Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/150.1)
-
Patent number: 6667035Abstract: The invention relates to monoclonal antibodies capable of recognizing and neutralizing epitopes from the ligand domain, the translocation domain or the catalytic domain of the enterotoxin (toxin A) and cytotoxin (toxin B) from Clostridium difficile, as well as their production and therapeutical and prophylactic applications to diseases due to the toxins.Type: GrantFiled: March 27, 2000Date of Patent: December 23, 2003Inventors: Christoph Von Eichel-Streiber, Michael Moos
-
Patent number: 6663873Abstract: An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the lipopolysaccharide (LPS) of Helicobacter bacteria, particularly the LPS of H. pylori or H. felis, or an immunogenic fragment thereof.Type: GrantFiled: August 9, 1996Date of Patent: December 16, 2003Assignee: CSLInventors: Christopher Vincent Doidge, Adrian Lee, Fiona Jane Buck, Elizabeth Pietrzykowski, Charles Alexander Quinn, Ian George Barr, Michael John Kleinig
-
Patent number: 6652857Abstract: The present invention includes methods for generating neutralizing antitoxin directed against verotoxins. In preferred embodiments, the antitoxin directed against these toxins is produced in avian species using soluble recombinant verotoxin proteins. This antitoxin is designed so as to be administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin, as well as for preventive treatment, and diagnostic assays to detect the presence of toxin in a sample.Type: GrantFiled: June 16, 1999Date of Patent: November 25, 2003Assignee: Promega CorporationInventors: James A. Williams, Lisa Marie Byrne, Charles S. G. Pugh
-
Publication number: 20030206907Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.Type: ApplicationFiled: April 9, 2003Publication date: November 6, 2003Inventor: Scott Koenig
-
Patent number: 6627728Abstract: The invention provides BASB010 polypeptides and polynucleotides encoding BASB010 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: July 16, 2001Date of Patent: September 30, 2003Assignee: SmithKline Beecham Biologicals s.a.Inventor: Joelle Thonnard
-
Patent number: 6627196Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.Type: GrantFiled: August 25, 2000Date of Patent: September 30, 2003Assignee: Genentech, Inc.Inventors: Sharon A. Baughman, Steven Shak
-
Patent number: 6623737Abstract: The invention is related to antibodies, particularly monoclonal antibodies, which recognize particularly epitopes of the intimin protein of enteropathogenic E. coli and enterohemorrhagic E. coli, methods of detecting such E. coli by use of these antibodies, and kits containing these antibodies for diagnosis.Type: GrantFiled: April 2, 1998Date of Patent: September 23, 2003Assignee: Imperial College of Science, Technology & MedicineInventors: Gordon Dougan, Gad Frankel
-
Patent number: 6610293Abstract: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.Type: GrantFiled: June 15, 1998Date of Patent: August 26, 2003Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Sunol Molecular CorporationInventors: Gerald W. Fischer, Richard F. Schuman, Hing Wong, Jeffrey R. Stinson
-
Patent number: 6600013Abstract: Provided are Moraxella catarrhalis BASB034 polypeptides and immnunogenic fragments of BASB034 polypeptides Preferably, the immunogenic fragments have at least 15 amino acids that match an aligned contiguous segment of SEQ ID NOs:2, 4, 6 or 8. The immunogenic fragments, when administered to a subject in a suitable composition (which can include an adjuvant, or a suitable carrier coupled to the fragment) raise an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:2, 4, 6 or 8. The invention further provides immunogenic compositions containing BASB034 polypeptides and immunogenic fragments thereof, and a pharmaceutically acceptable carrier. Also provided are fusion proteins that contain BASB034 polypeptides and immunogenic fragments thereof.Type: GrantFiled: May 14, 2001Date of Patent: July 29, 2003Assignee: SmithKline Beecham Biologicals S.A.Inventor: Jean-Louis Ruelle
-
Patent number: 6585976Abstract: The invention concerns Mycobacterium strains whereof the erp gene is modified and a vaccine composition containing same. The modification of the erp gene decreases the virulence and the persistence of the Mycobacterium strains.Type: GrantFiled: May 10, 2000Date of Patent: July 1, 2003Assignee: Institut PasteurInventors: Brigitte Gicquel, François-Xavier Berthet
-
Patent number: 6582925Abstract: The use of genetic methodology based on the fusion of the proteins with the alcaline phosphatase (Lim et al., 1995) has allowed the isolation of a new exported protein of M. tuberculosis. In the present article, first of all the isolation of a gene encoding this exported protein called DES is described as well as its characterization and its distribution among the different mycobacterial species. It is notably shown that the protein has in its primary sequence amino acids only found at the level of active sites of enzymes of class II diiron-oxo proteins family. Among the proteins of this family, DES protein of M. tuberculosis does not present significative homologies with stearoyl ACP desaturases. Secondly, the antigenic feature of this protein has been studied. For this, DES protein of M. tuberculosis has been overexpressed in E. coli under recombinant and purified protein form from this bacterium. The reactivity of tuberculous patients sera infected by M. tuberculosis or M.Type: GrantFiled: April 20, 1999Date of Patent: June 24, 2003Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 6551599Abstract: The present invention is directed to a method of producing monoclonal antibodies that are highly specific for (1) unique epitopes of Campylobacter jejuni (Cj) only and (2) epitopes conserved between Campylobacter jejuni and Campylobacter coli (Cc) outer membranes; to specific monoclonal antibodies made by the methods of the instant invention; and uses thereof The invention is drawn further to immunogens comprising the outer membrane complexes of Cj and Cc.Type: GrantFiled: March 16, 2001Date of Patent: April 22, 2003Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Robert E. Mandrell, Anna H. Bates, David L. Brandon
-
Patent number: 6544516Abstract: The present invention provides bacterial and fungal ABC transporter proteins, immunogenic fragments thereof, neutralizing agents specific thereto and binding agents specific thereto for therapeutic and diagnostic use, together with diagnostic test methods, methods of same and kits for performing same. Also provided are immunodominant conserved antigens from gram positive staphylococci, together with neutralising and binding agents specific thereto for use in therapy and diagnosis, and methods of same. Also provided are Staphylococcal homologues of IstA and IstB and immunogenic fragment thereof, and their uses in methods of treatment and diagnosis of the human or animal body.Type: GrantFiled: January 4, 1999Date of Patent: April 8, 2003Assignee: NeuTec Pharma plcInventors: James Peter Burnie, Ruth Christine Matthews
-
Patent number: 6537550Abstract: The present invention relates to use of avian antibodies and/or antigen binding fragments thereof, for the production of a drug for treatment and/or prevention of respiratory tract infection. The drug is administered through local application at the oral cavity and/or pharynx.Type: GrantFiled: September 20, 1999Date of Patent: March 25, 2003Assignee: Immun System I.M.S. ABInventors: Anders Larsson, Hans Kollberg
-
Patent number: 6517829Abstract: New products are provided comprising inactivated lower eukaryotic cells, preferably yeasts or molds, having at the outer surface functionally active antibodies or functionally active fragments thereof. Preferred antibody fragments are the variable domains of Camelidae heavy chain antibodies, which are surprisingly stable against physical and chemical decontamination regimes and do not loose their activity when they are immobilized on the glucan layer of the cell wall which is present in a variety of lower eukaryotes. The new products are preferably in the field of food products, personal care products, and animal feed products.Type: GrantFiled: March 12, 1999Date of Patent: February 11, 2003Assignee: Unilever Patent Holdings BVInventors: Leon Gerardus Joseph Frenken, Michael Marie Harmsen, Richard Hendricus Jacobus van der Linden, Cornelis Theodorus Verrips
-
Patent number: 6517845Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.Type: GrantFiled: November 12, 1999Date of Patent: February 11, 2003Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
-
Patent number: 6482602Abstract: Reagents and methods for the detection of Staphylococcus aureus are provided. The reagents contain an antibody that binds to a capsular polysaccharide of type 5 of Staphylococcus aureus, and can be used in methods for detection of oxacillin resistant Staphylococcus aureus that escapes detection by agglutination in the presence of fibrinogen and antibodies directed against protein A of Staphylococcus.Type: GrantFiled: August 8, 2000Date of Patent: November 19, 2002Assignee: Institut PasteurInventors: Jean-Michel Fournier, Alain Boutonnier
-
Publication number: 20020164337Abstract: Monoclonal and polyclonal antibodies to the binding subdomains of the MAP protein, including the Map10 protein, or other immunogenic subregions of the MAP protein, are provided which can be useful in the treatment of and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they serve the double purpose of preventing adherence of the bacteria to host cells and enhancing the killing of the bacteria in an infected host.Type: ApplicationFiled: October 22, 2001Publication date: November 7, 2002Inventors: Joseph M. Patti, Paul Domanski, Pratiksha Patel
-
Publication number: 20020160005Abstract: Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to the individual in need of treatment or protection.Type: ApplicationFiled: January 7, 2002Publication date: October 31, 2002Applicant: TRUSTEES OF TUFTS COLLEGEInventors: Saul Tzipori, Ramaswamy Balakrishnan, Arthur Donohue-Rolfe
-
Publication number: 20020155114Abstract: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: ApplicationFiled: August 31, 1998Publication date: October 24, 2002Inventors: JAMES D. MARKS, PETER AMERSDORFER
-
Patent number: 6458366Abstract: Compounds and methods for diagnosing tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of one or more M. tuberculosis proteins, and DNA sequences encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of M. tuberculosis infection in patients and biological samples. Antibodies directed against such polypeptides are also provided.Type: GrantFiled: May 5, 1998Date of Patent: October 1, 2002Assignee: Corixa CorporationInventors: Steven G. Reed, Yasir A. W. Skeiky, Davin C. Dillon, Antonio Campos-Neto, Raymond Houghton, Thomas S. Vedvick, Daniel R. Twardzik, Michael J. Lodes, Ronald C. Hendrickson
-
Patent number: 6458933Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.Type: GrantFiled: May 19, 1999Date of Patent: October 1, 2002Assignee: Immunomedics, Inc.Inventor: Hans J. Hansen
-
Publication number: 20020136727Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, harvesting the eggs which contain antibodies to the immunogen, drying the egg contents and adding to the feed or water for the host animals.Type: ApplicationFiled: December 26, 2001Publication date: September 26, 2002Inventors: Peter Nash, John W. Rosevear, D. L. Robinson, Donald L. Robinson
-
Patent number: 6455039Abstract: The present invention relates to parasitic helminth macrophage migration inhibitory factor (MIF) proteins; to parasitic helminth MIF nucleic acid molecules, including those that encode such MIF proteins; to antibodies raised against such MIF proteins; and to compounds that inhibit parasitic helminth MIF activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.Type: GrantFiled: January 30, 2001Date of Patent: September 24, 2002Assignee: Heska CorporationInventors: Cynthia Ann Tripp, Kevin S. Brandt, Nancy Wisnewski
-
Patent number: 6455673Abstract: Disclosed are diphtheria toxin polypeptides having multiple mutations, which render the polypeptides useful as vaccines.Type: GrantFiled: February 16, 1999Date of Patent: September 24, 2002Assignee: President and Fellows of Harvard CollegeInventor: R. John Collier
-
Publication number: 20020131969Abstract: Compositions and kits comprising combinations of &bgr;-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which &bgr;-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.Type: ApplicationFiled: February 22, 2002Publication date: September 19, 2002Applicant: NABIInventors: Viliam Pavliak, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20020110562Abstract: The present invention relates to novel immunogenic polypeptides, and fragments thereof, and vaccines for the prevention and treatment of pneumococcal infection, especially by Streptococcus pneumoniae. The invention also relates to antibodies against the disclosed polypeptides, as well as vaccines containing said polypeptides and methods of disease prevention.Type: ApplicationFiled: February 5, 2002Publication date: August 15, 2002Inventors: John E. Adamou, Gil H. Choi
-
Publication number: 20020102262Abstract: Disclosed are the cna gene and cna-derived nucleic acid segments from Staphylococcus aureus, and DNA segments encoding cna from related bacteria. Also disclosed are Col binding protein (CBP) compositions and methods of use. The CBP protein and antigenic epitopes derived therefrom are contemplated for use in the treatment of pathological infections, and in particular, for use in the prevention of bacterial adhesion to Col. DNA segments encoding these proteins and anti-(Col binding protein) antibodies will also be of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of bacterial colonization in an animal such as a human. These DNA segments and the peptides derived therefrom are contemplated for use in the preparation of vaccines and, also, for use as carrier proteins in vaccine formulations, and in the formulation of compositions for use in the prevention of S. aureus infection.Type: ApplicationFiled: March 22, 2001Publication date: August 1, 2002Inventors: Magnus Hook, Joseph M. Patti, Karen House-Pompeo
-
Patent number: 6419925Abstract: The present invention relates to the identification of toxoplasma gondii antigens and the preparation thereof by genetic engineering. A cDNA expression gene bank of this parasite was prepared. Recombinant clones which are of diagnostic interest were identified using a high-titer rabbit anti-Toxoplasma gondii serum, and isolated.Type: GrantFiled: October 3, 2001Date of Patent: July 16, 2002Assignee: Dade Behring Marburg GmbHInventors: Stefan Knapp, Robert Ziegelmaier, Hans Küpper
-
Patent number: 6416962Abstract: The invention relates to a method for identifying a Mycobacterium species responsible for a mycobacterial infection in human or animal, comprising selecting a suitable mycobacterial species and strain; preparing at least one mycobacterial antigen, respectively antigen preparation; binding the antigen, respectively the antigen preparation to a suitable carrier; causing the binding antigen to react with antibodies from serum of an individual infected with a Mycobacterium species; making visible antigen-antibody reactions for a suitable antibody (sub-)class; and identifying the responsible Mycobacterium species on the basis of the reactions which are made visible. The invention further provides a diagnostic kit which takes the form of a dip-stick on which is arranged a carrier strip with mycobacterial antigens binding thereto, and means for visualizing antigen-antibody reactions occurring on the carrier after contact with the serum for testing.Type: GrantFiled: October 5, 1998Date of Patent: July 9, 2002Assignee: Kreatech Biotechnology B.V.Inventors: Pranab Khumar Das, Remco Maria Van Es, Hendrik Jan Houthoff
-
Patent number: 6416968Abstract: This invention relates to methods of screening molecules capable of inhibiting the survival of Helicobacter pylori in vivo by specifically inhibiting the activity of UreI, to the molecules identified by these methods, and to the use of these molecules to treat or prevent H. pylori infection.Type: GrantFiled: August 23, 2000Date of Patent: July 9, 2002Assignee: Institut PasteurInventors: Hilde De Reuse, Stéphane Skouloubris, Valérie Cussac, Agnès Labigne
-
Publication number: 20020086020Abstract: This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.Type: ApplicationFiled: January 10, 2002Publication date: July 4, 2002Applicant: OSEL, INC.Inventor: Peter P. Lee
-
Publication number: 20020081300Abstract: The invention provides methods and compositions for alleviating the symptoms of diabetes with a pharmaceutical composition including a combination of anti-glutamic acid decarboxylase (anti-GAD) and anti-insulin antibodies.Type: ApplicationFiled: July 30, 2001Publication date: June 27, 2002Inventor: John McMichael
-
Publication number: 20020068818Abstract: A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.Type: ApplicationFiled: August 9, 2001Publication date: June 6, 2002Inventor: Vince Pozsgay
-
Patent number: 6399066Abstract: A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.Type: GrantFiled: September 10, 1999Date of Patent: June 4, 2002Assignee: The Brigham and Women's Hospital, Inc.Inventor: Gerald B. Pier
-
Patent number: 6395282Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria. The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.Type: GrantFiled: April 16, 1999Date of Patent: May 28, 2002Assignee: University of RochesterInventors: Andrew S. Kende, Barbara H. Iglewski, Roger Smith, Richard P. Phipps, James P. Pearson
-
Publication number: 20020061306Abstract: A protein is described which is capable of binding to &agr;2 macro globulin. The protein comprises the amino acid sequence of SEQ ID No: 1 or a functional variant thereof. The invention also relates to a peptide comprising a fragment of the protein of at least six amino acids in length. A protein or peptide which is capable of generating a protective immune response to Group A streptococcus comprises the amino acid sequence of SEQ ID No: 1, a functional variant thereof or a functional variant of at least six amino acids in length of either thereof. Such a protein or peptide may be used in a vaccine composition together with a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 1, 2001Publication date: May 23, 2002Inventors: Lars Bjorck, Magnus Rassmussen
-
Patent number: 6383763Abstract: The present invention is directed to methods and compositions for the detection of infection and disease due to members of the genus Mycobacterium. In particular, the present invention is well-suited to the detection and identification of patients with disease or infection due to M. tuberculosis or MAC.Type: GrantFiled: July 26, 1996Date of Patent: May 7, 2002Assignee: Case Western Reserve UniversityInventor: Robert S. Wallis
-
Publication number: 20020051788Abstract: A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.Type: ApplicationFiled: August 1, 2001Publication date: May 2, 2002Inventor: Vince Pozsgay
-
Patent number: 6379902Abstract: Mycobacterium tuberculosis protein having a molecular weight of 28 779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.Type: GrantFiled: August 1, 1997Date of Patent: April 30, 2002Assignee: Institut PasteurInventors: Anne Laqueyrerie, Gilles Marchal, Pascale Pescher, Felix Romain
-
Patent number: 6376203Abstract: Mouse is immunized with an antigen of a lipid fraction originating from Mycoplasma fermentans. Its spleen cells are fused with mouse myeloma cells to prepare hybridomas. A hybridoma is selected, which produces a monoclonal antibody having reaction specificity to GGPL-III that is a phosphocholine-containing glycoglycerolipid specific to Mycoplasma fermentans. Mycoplasma fermentans is detected by using the obtained antibody.Type: GrantFiled: July 8, 1999Date of Patent: April 23, 2002Assignee: Seikagaku CorporationInventors: Kazuhiro Matsuda, Naoki Yamamoto
-
Publication number: 20020039579Abstract: An inhibitor composition of Helicobacter pylori adhesion in the stomach comprises (1) anti-urease antibodies obtained from eggs laid by hens which have been immunized against H. pylori urease and (2) an inhibitor of gastric acid secretion. This inhibitor is capable of completely eliminating H. pylori from the stomach, so it is useful for the prevention or treatment of diseases caused by infection of H. pylori such as peptic ulcers.Type: ApplicationFiled: July 13, 2001Publication date: April 4, 2002Inventors: Yoshikatsu Kodama, Nobutake Kimura
-
Patent number: 6355235Abstract: Certain antibody molecules are so stable and so potent at immobilizing sperm as well as the pathogens for sexually transmitted diseases (STDs) that they make possible new prophylactic contraceptive methods: (a) for men, a skin lotion containing antibodies against sperm and against STD pathogens to be applied to the penis and external genitals during sexual activity, thereby delivering prophylactically effective doses of antibodies to virtually all areas of skin and epithelia across which most STDs, including AIDS, are usually transmitted, and, during vaginal intercourse, the penis will deliver a contraceptively reliable dose of the antibodies to the cervical region of the vagina; and (b) for women, intrauterine devices (IUDs) and intravaginal devices (IVDS) that release antibodies into the uterus or into the vagina to provide continuous protection against pregnancy and STDs for periods of months to years.Type: GrantFiled: November 23, 1999Date of Patent: March 12, 2002Assignee: Johns Hopkins UniversityInventors: Richard A. Cone, Kevin J. Whaley
-
Publication number: 20020025318Abstract: Iron-regulated, outer membrane proteins found in Neisseria gonorrhoeae and Neisseria meningitidis are important in transferrin receptor function. The proteins, which are isolatable by means of a transferrin affinity column, bind specifically to antisera raised against an iron-regulated outer membrane protein having a molecular weight of approximately 100 kD found in Neisseria gonorrhoeae.Type: ApplicationFiled: June 14, 1999Publication date: February 28, 2002Applicant: University of North CarolinaInventors: P. FREDERICK SPARLING, CYNTHIA NAU CORNELISSEN
-
Patent number: 6350449Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like, as well as antibodies to these conjugate vaccines. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.Type: GrantFiled: July 20, 1999Date of Patent: February 26, 2002Assignee: Baxter International Inc.Inventors: Harold J. Jennings, Robert Pon, Michele Lussier, Francis Michon
-
Patent number: 6322788Abstract: Compositions containing a purified antibody having both an antigen-binding portion specific for a bacterial antigen and a constant region that does not bind bacterial Fc-binding proteins are disclosed. Also disclosed are compositions and methods for treating and preventing bacterial infections in animals and humans.Type: GrantFiled: August 20, 1999Date of Patent: November 27, 2001Inventor: Stanley Arthur Kim
-
Patent number: 6309641Abstract: An antigenic preparation is provided which contains a 63 Kd outer membrane protein from Leptospira which can be used immunologically as a vaccine for leptospirosis caused by this organism. Also provided in the invention are polynucleotides encoding the protein and antibodies which bind the protein which are useful in the diagnosis and treatment of leptospirosis.Type: GrantFiled: October 20, 1998Date of Patent: October 30, 2001Assignee: The University of California Los AngelesInventor: David A. Haake
-
Publication number: 20010026798Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.Type: ApplicationFiled: March 2, 2001Publication date: October 4, 2001Inventor: Scott Koenig
-
Patent number: 6296849Abstract: All Borrelia burgdorferi sensu lato isolates characterized to date have one or a combination of several major outer surface proteins (Osp). Mutants of B. burgdorferi lacking Osp proteins were selected with polyclonal or monoclonal antibodies at a frequency of 10−6 to 10−5. One mutant that lacked OspA, B, C and D was further characterized in the present study. It was distinguished from the OspA+B+ cells by its (i) auto-aggregation and slower growth rate, (ii) decreased plating efficiency on solid medium, (iii) serum- and complement-sensitivity, and (iv) diminished capacity to adhere to human umbilical vein endothelial cells. The Osp-less mutant was unable to evoke a detectable immune response after intradermal live cell immunization even though mutant survived in the skin the same duration as wild-type cells.Type: GrantFiled: October 4, 1999Date of Patent: October 2, 2001Assignee: Board of Regents, The University of Texas SystemInventors: Ariadna Sadziene, Alan G. Barbour
-
Patent number: 6294171Abstract: The invention provides methods and compositions for treating the symptoms of disease states associated with the presence of a toxin or infectious agent having the step of administering an antibody specific for the toxin or infectious agent at a dosage of less than 0.1 mg per day.Type: GrantFiled: January 31, 2001Date of Patent: September 25, 2001Assignee: Milkhaus Laboratory, Inc.Inventor: John McMichael